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larisation service, supports the following
observations. There is an increasing prob-
lem in the United States when randomised
controlled trials are timed to follow on from
lengthy uncontrolled non-randomised stud-
ies, often in the same centres. The reluctance
of American doctors and patients to take
part in a randomised controlled trial of
transmyocardial revascularisation led to the
crossover design and short term follow up,
both features that were criticised by the
Food and Drug Administration.1 2
To avoid such problems in Britain the
health technology assessment process needs
to be sufficiently responsive to ensure that
randomised controlled trials of new tech-
nologies are conducted in a timely manner.
There may also be a case for more
cooperation between centres, a proposition
arising from our second observation, which
concerns recruitment to the British trial of
transmyocardial revascularisation. We should
have reported definitive results last autumn,
but, because recruitment was slower than
expected, a one year extension was agreed
with the Medical Research Council, at
additional cost. Although efforts have been
made to publicise the trial widely, the uneven
pattern of referral, with higher numbers from
local regions, does not reflect the geographi-
cal distribution of coronary artery disease.
Maybe an additional trial centre located in
the north of the country would have resulted
in more rapid recruitment. The NHS
research and development health technology
assessment programme, the Medical
Research Council, and other major funders
could play a part in encouraging grant appli-
cants to work together to complete such trials
as quickly and efficiently as possible. In the
meantime, the jury in the trial of transmyo-
cardial revascularisation is still out.
Noreen Caine Director of research and development
Peter M Schofield Consultant cardiologist
John Wallwork Medical director
Papworth Hospital NHS Trust, Cambridge
CB3 8RE
Linda D Sharples Statistician
MRC Biostatistics Unit, Institute of Public Health,
University of Cambridge, Cambridge CB2 2SR
1 Josefson D. Experimental angina treatment rejected by the
FDA. BMJ 1997;315:328. (9 August.)
2 Ault A. Heart laser falters. Lancet 1997;350:420.
Comparison of assays for
measuring plasma paracetamol
Possibility of calibration error needs
evaluation
Editor—Egleston et al report a significant
difference in plasma paracetamol concen-
trations assayed with the AcetaSite bench
assay and a standard laboratory assay.1
Rapid and accurate determinations of
plasma paracetamol concentrations are cru-
cial in the expeditious and appropriate
administration of antidotal treatment, which
prevents severe liver damage if given
sufficiently early in the course of poisoning.2
We compared two methods for estimat-
ing plasma paracetamol (Cobas paraceta-
mol assay kit (Cambridge Life Sciences, Ely)
and AcetaSite blood acetaminophen (para-
cetamol) test (Cambridge Life Sciences))
with a standard high performance liquid
chromatographic method.3 We used the
methods on 35 samples from 23 patients
presenting between 5 and 50 hours after
a paracetamol overdose who claimed to
have taken a mean of 22.0 g (range 5-50
(SD 13.1) g) of paracetamol alone. Samples
were taken and stored at − 40°C, and all
assays were performed in our laboratory.
The figure shows the results obtained
with the three methods. Compared with high
performance liquid chromatography, the
AcetaSite assay overestimated plasma para-
cetamol concentration in a considerable
number of cases; the difference was signifi-
cant (P = 0.002, paired t test). There was no
significant difference between the results
obtained with the Cobas assay and high per-
formance liquid chromatography (P = 0.81,
paired t test. The Pearson correlation
coefficients of the AcetaSite and Cobas assays
with standard high performance liquid chro-
matography were 0.97 and 0.97 respectively.
We believe that the most likely source of
the discrepancy between the AcetaSite assay
and the other methods in our study was a
calibration error within the AcetaSite
method. All assays were carried out in our
laboratory by an experienced clinical chemist
(by contrast, some of the assays in Egleston et
al’s study were done by emergency doctors).
We therefore believe that operator error is an
unlikely explanation for the results of our
study or those of the study reported by Egles-
ton et al. The possibility of a calibration error
in the AcetaSite system requires further
evaluation; external calibration is not possible
with this assay.
Egleston et al do not make clear what
results they obtained in the 100 patients who
had apparently not taken paracetamol but
from whom blood was taken for assay. These
results should have been negative by both
methods; this is an important point for exclu-
sion of false positive results. In patients who
admit to having taken paracetamol, interfer-
ence in the assay by other drugs taken
concurrently is a potential source of error.
A L Jones Deputy director
Scottish Poisons Information Bureau, Edinburgh
Royal Infirmary, Edinburgh EH3 9YW
D R Jarvie Senior clinical scientist
D Simpson Senior lecturer
University Department of Clinical Biochemistry,
Edinburgh Royal Infirmary
L F Prescott Professor of clinical pharmacology,
Western General Hospital Clinical Pharmacology
Unit, Edinburgh EH4 2XU
1 Egleston CV, Browning C, Hamdi I, Campbell-Hewson G,
Robinson SM. Comparison of two assays for measuring
plasma concentrations of paracetamol. BMJ 1997;
315:991-2. (18 October.)
2 Prescott LF, Illingworth RN, Critchley JAJH, Stewart MJ,
Adam RD, Proudfoot AT. Intravenous N-acetylcysteine: the
treatment of choice for acetaminophen poisoning. BMJ
1979;ii:1097-100.
3 Adriaenssens PI, Prescott LF. High performance liquid
chromatographic estimation of paracetamol metabolises
in plasma. Br J Clin Pharmacol 1978;6:87-8.
Training and education in use of assay
are important
Editor—Egleston et al compared the
accuracy of a standard laboratory paraceta-
mol assay with that of a rapid bedside test
(AcetaSite).1 Egelston et al used a statistical
method developed by Bland and Altman2 to
assess agreement between the two methods
of clinical measurements. The limits of
agreement were calculated to be 0.16 and
5.04. This translates into poor agreement
between the two assays, with 95% of values
obtained with AcetaSite being between 0.16
and 5.04 times the values obtained with the
laboratory assay. The authors concluded
that the AcetaSite test should not replace the
established laboratory method.
We have also evaluated the AcetaSite
test, recruiting 58 patients to our study. Four
sets of results were excluded from the analy-
sis because the Stat-Site meter recorded a
maximum of > 250 mg/l (by contrast, the
laboratory gave a specific reading). At the
lower end of the range ( < 20 mg/l ) 15 sets
were excluded for similar reasons. On the
remaining 39 samples, using Bland and Alt-
man’s test, we found our limits of agreement
to be 0.79 and 1.1. Our results therefore
suggest good agreement between the two
assays. The performance (r = 0.974) matches
closely that shown in the datasheet for
AcetaSite compared with standard reagents
(r = 0.97 and r = 0.983).
When evaluating a new technology, such
a contrast between studies merits careful
analysis. Egleston et al make some sugges-
tions for the reason for the poor agreement
between the two assays in their study.
Although there may be other reasons, the
most likely is training and education. Our
study was carried out by the six middle
grade doctors in the accident and emer-
gency department and a small number of
senior house officers after a one to one
training programme. An algorithm card was
used from the outset (modified after
piloting). Particular attention should be paid
to this much overlooked aspect of study
design if accurate results are to be attained
and valid conclusions drawn.
We believe that the AcetaSite test does
provide a rapid and accurate bedside assay
of paracetamol concentrations. Further
analysis in our study, however, indicates that
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